Jung HA, Park B, Park S, Sun JM, et al. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis. Lung Cancer 2024;190:107536.
PMID: 38493759